McCann, Kelly E.
Goldfarb, Shari B.
Traina, Tiffany A. http://orcid.org/0000-0003-3597-0050
Regan, Meredith M.
Vidula, Neelima http://orcid.org/0000-0002-5963-7052
Kaklamani, Virginia http://orcid.org/0000-0002-3313-8458
Funding for this research was provided by:
TerSera Therapeutics
Article History
Received: 8 September 2023
Accepted: 3 January 2024
First Online: 19 January 2024
Competing interests
: K.E.M. discloses clinical trial research support to her institution from Gilead Sciences, H3 Biomedicine, ZWI Therapeutics, Eli Lilly, Olema Oncology, G1 Therapeutics, AstraZeneca; receives consulting fees from Puma Biotechnology; receives honoraria from OncLive, Best of ASCO, Physicians’ Education Resource, Eli Lilly’s speaker’s bureau and Dava Oncology; receives support for attending meetings from Eli Lilly and Dava Oncology; and participates on the advisory board for Daiichi Sankyo, Puma Biotechnology, Sermonix and Eli Lilly. T.A.T. reports research support (grants) to her institution from Pfizer, AstraZeneca, Genentech/Roche, Daiichi Sankyo, Ayala Pharmaceuticals and Astellas Pharma; consulting fees from Pfizer, AstraZeneca, Genentech/Roche, Daiichi Sankyo, Merck, Gilead Sciences, Novartis, GlaxoSmithKline, GE Healthcare, Biotheranostics, Hengrui Pharmaceuticals, G1 Therapeutics, TerSera Therapeutics, Stemline Therapeutics and Exact Sciences; and an advisory role with I-SPY trial data safety and monitoring board. M.M.R. reports research support (grants) and/or consulting fees to her institution from AstraZeneca, Bayer, Biotheranostics, Bristol-Myers Squibb, Debiopharm, Ipsen, Novartis, Pfizer, Roche, Tolmar and TerSera Therapeutics; honoraria from Bristol-Myers Squibb; and an advisory role with AstraZeneca, Bristol-Myers Squibb, TerSera Therapeutics and Tolmar. N.V. discloses research funding to her institution from Merck, Dae Hwa, Radius, Novartis, Pfizer; and participation in advisory boards for Gilead Sciences, TerSera Therapeutics, Aadi Bioscience, OncoSec Medical, AbbVie and the steering committee for the Stemline study. V.K. receives royalties from UpToDate and honoraria from Gilead Sciences, AstraZeneca and Seagen; consults for Puma Biotechnology, AstraZeneca, Menarini Group, and Eli Lilly; and participates on an advisory board for Bristol-Myers Squibb.